Jonathan Aschoff

Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results

Inovio Analyst: COVID-19 Competition Could Be Too Great

Roth Downgrades Inovio On Vaulation Despite Positive MERS Vaccine Data

Inovio Analyst: COVID-19 Competition Could Be Too Great

Roth Downgrades Inovio On Vaulation Despite Positive MERS Vaccine Data

Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines

If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi's Bid

Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines

If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi's Bid

Brean Initiates Alder BioPharma At Buy, $45 Price Target

Brean Initiates SCYNEXIS With Buy Rating, $16 Price Target

Jonathan Aschoff Recent News

Focalin Sales May Be Weak...But It Won't Hurt This Stock

Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying

Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?

Alexion Pharmaceuticals Is Still A Buy, Despite Rx Kanuma's Review-Date Delay

Biotech Pair Trade? Brean Weighs In On Keryx Biopharma And Rockwell Medical

Cantor, Brean Capital Like Celldex Therapeutics Following Positive Data For Brain Tumor Therapy

Is Keryx Still A Good Buy After Weak Prescription Data?

Analyst: Chimerix Govt. Smallpox Pact Worth Up To $435 Million

Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream

Is Tetraphase Pharmaceuticals A Buyout Candidate? Brean Capital Thinks So

Brean Predicts 'A Skid And A Crash' For Rockwell Medical's Triferic Drug

UPDATE: Brean Capital Raises PT On Chimerix On Broad Antiviral Coverage

Brean Capital's Top Ideas For 2015

UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence

Brean Capital Sees No Surprises In 3Q14 Report For Repros Therapeutics

UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

Dendreon Plunges on Restructuring News; Stock Downgraded